Over the past decade, the therapeutic landscape of MM has been revolutionised by the invention of immune check point inhibitors (ICPIs) and targeted BRAF/MEK inhibitors (BRAFi/MEKi) [46,47,48]. Here, BRAF is linked to Miyoshi myopathy.